MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...

MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced. The US pharma ...

This document contains a basic tutorial and training exercise for getting started using the VIC model. It assumes that you have a working knowledge of Linux/Unix, and that you have access to a Purdue ...